Dr. Min Li is currently the Chief Scientist of Huahai Pharmaceutical, Co., Ltd. responsible for analytical research and development. He received his PhD in Organic Chemistry from The Johns Hopkins University in 1991. Following a postdoctoral research in medicinal chemistry, he had worked for several multinational pharmaceutical companies with increasing responsibilities, including Roche, Merck & Co., Inc., Schering-Plough, and Merck again.

Over the 16 years at Merck, he led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity research and qualification, study of drug degradation chemistry, analytical development, and support for new drug filing (NDA). In 2014, he joined Huahai Pharmaceutical, a leading Chinese pharmaceutical company with operations in both China and US, as Vice President for Analytical Operation. He established the Center of Excellence for Modern Analytical Technologies (CEMAT), a technical core group with more than 150 scientists for solving the most challenging technical problems from pharmaceutical R&D to scale-up and production at Huahai. Between June 2020 and May 2023, Dr. Li was also fully responsible for Huahai's small molecule innovative drug research and development in the capacity of Board Chair and General Manager of Shanghai Synergy Pharmaceutical Sciences Co., Ltd, a wholly owned subsidiary of Huahai. During the three year tenure, his team successfully brought two investigational new drug applications (INDs) into clinical stage, one of which is currently in phase II clinical trial, and determined several candidates for pre-clinical studies. Dr.

Li published a single-authored book, "Organic Chemistry of Drug Degradation" (by Royal Society of Chemistry) in 2012. He is the first/communicating author of approximately 60 publications in organic, medicinal, bioconjugate, and analytical chemistry (including mass spectrometry), and inventor/co-inventor of greater than 20 patents or patent applications. Dr. Li was the president of Sino-American Pharmaceutical and Professional Association (SAPA) between 2003 and 2004. He has been a member of the expert committee (Chemical Medicines 5) at United States Pharmacopoeia (USP) since 2015.